Nitesh Ainani, MD
Interventional Cardiology · Pawleys Island, SCNPI 1952718074
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,410 of the $10,201 with a category attached, or 62.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.1%.
Across 220 payments — averaging $46.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Edwards Lifesciences$1K
- Boston Scientific$1K
- Abbott$898
- Stryker$763
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$501
- plus $3K from 25 others
What the payments were for
- Grants$1,10511%
- Travel & lodging$2,27022%
- Food & beverage$6,41063%
- Education$4164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 21 | $1,743 |
| Edwards Lifesciences | 8 | $1,480 |
| Boston Scientific | 13 | $1,416 |
| Abbott | 21 | $898 |
| Stryker | 6 | $763 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $501 |
| Abiomed | 8 | $477 |
| Cvrx, Inc. | 9 | $442 |
| E.r. Squibb & Sons, L.L.C. | 13 | $383 |
| Novartis | 20 | $344 |
| Amgen | 11 | $203 |
| Merck | 10 | $184 |
| Pfizer | 9 | $182 |
| Alnylam Pharmaceuticals Inc. | 8 | $164 |
| Boehringer Ingelheim | 9 | $161 |
| AstraZeneca | 8 | $114 |
| Shockwave Medical, Inc | 3 | $111 |
| Bridgebio Pharma, Inc. | 4 | $101 |
| Astellas Pharma US Inc | 1 | $100 |
| Scpharmaceuticals Inc. | 4 | $92 |
| Penumbra, Inc. | 1 | $54 |
| Esperion Therapeutics, Inc. | 2 | $47 |
| Novo Nordisk | 2 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Baxter Healthcare | 2 | $35 |
| Philips North America LLC | 1 | $30 |
| Cardiovascular Systems Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL$1,105
- SYMPLICITY G3$400
- OPTIS$340
- CLOTTRIEVER BOLD CATHETER$309
- FlowTriever$304
- Resolute$258
- Barostim Neo System$238
- CAMZYOS$237
- VenaSeal$175
- Impella$150
- FLOWTRIEVER CATHETER, S$135
- CT THROMBECTOMY SYSTEM KIT$135
- CHOICE$121
How this compares
$10,201 in reported general payments places this provider in the 55th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 458 | $501,966 |
| EntrestoSacubitril/Valsartan | 97 | $105,453 |
| FarxigaDapagliflozin Propanediol | 123 | $93,092 |
| BrilintaTicagrelor | 176 | $87,351 |
| XareltoRivaroxaban | 76 | $76,618 |
| JardianceEmpagliflozin | 51 | $47,544 |
| VascepaIcosapent Ethyl | 46 | $23,257 |
| Repatha SureclickEvolocumab | 25 | $20,142 |
| Repatha SyringeEvolocumab | 15 | $16,439 |
| Metoprolol Succinate | 559 | $7,994 |
| Ezetimibe | 188 | $5,541 |
| Icosapent Ethyl | 23 | $4,801 |
| Rosuvastatin Calcium | 350 | $4,447 |
| Atorvastatin Calcium | 376 | $3,659 |
| Bumetanide | 34 | $2,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $182 | $501,966458 claims |
| AstraZenecaFarxiga, Brilinta | $114 | $180,443299 claims |
| NovartisEntresto | $344 | $105,45397 claims |
| Johnson & JohnsonXarelto | $20 | $76,61876 claims |
| Boehringer IngelheimJardiance | $161 | $47,54451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Pawleys Island
- Nicholas AmorosoPawleys Island$283K
- Thomas TodoranPawleys Island$95K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
- Robert LeonardiWest Columbia$203K
- Anbukarasi MaranCharleston$132K
- Jesse JorgensenGreenville$102K
- Michael CryerColumbia$92K
- Josh DollGreenville$79K
- Loren MorganColumbia$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.